HACKENSACK, N.J., Nov. 17,
2016 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR),
engaged in the development of advanced technology solutions and
services to personalize the development and use of oncology drugs,
announced today the signing of a $2
million contract with a large pharmaceutical customer.
This is the largest pre-clinical pharmacology contract in the
company's history and is almost double the size of the largest
previous contract. The contract includes studies utilizing
Champions patient derived xenograft (PDX) models and a significant
component of work on immune oncology drugs. Champions
continues to invest in its capabilities for customers interested in
testing immune oncology drugs and this contract represents an
important step forward in commercializing these capabilities.
Dr. Ronnie Morris, Champions
Oncology's President commented, "This is an important milestone for
Champions Oncology. This contract demonstrates our ability to
build on our existing customer relationships by growing the use of
our pre-clinical PDX product and adding related products to our
offering. We have a great opportunity to leverage the
relationships we have developed with almost 150 customers and the
reputation for quality that we have earned. We have been
focused on accelerated revenue growth and achieving profitability
in the near term. This contract furthers our efforts on both of
these fronts while establishing an important foundation for growth
in future fiscal years."
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of
advanced technology solutions and services to personalize the
development and use of oncology drugs. The company's technology
platform is a novel approach to personalizing cancer care based
upon the implantation of primary human tumors in immune-deficient
mice to create TumorGrafts that preserve the biological
characteristics of the original human tumor in order to determine
the efficacy of a treatment regimen. The company uses this
technology in conjunction with related services to offer solutions
for two customer groups: Personalized Oncology Solutions, in which
results help guide the development of personalized treatment plans,
and Translational Oncology Solutions, in which pharmaceutical and
biotechnology companies seeking personalized approaches to drug
development can lower the cost and increase the speed of developing
new drugs. For more information, please
visit www.championsoncology.com.
One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 201-808-8400
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/champions-oncology-signs-2-million-contract-300365409.html
SOURCE Champions Oncology, Inc.